FDA Grants Orphan Drug Designation to AUM302 for Neuroblastoma A global clinical-stage biotech company, AUM Biosciences, focused on discovering and developing precision oncology therapeutics, decla...
Mainstay Medical Published Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study On November 22, 2022, Mainstay Medical, a medical devices company, announced that the data from the ReActiv8®-C study, a single-centre, real-world study with a one-year clinical follow-up of selected patients, is publ...
Find More
Sleep disorders (or sleep-wake disorders) are one of the major health burdens in today's time. Sleep is a fundamental process in human life and well-being, and these disorders largely remain untreated or, more often, misdiagnosed as psychiatric problems. Sleep disorders affect and change the way that a person sleep...
Find More
RNA interference (RNAi) is a fundamental gene-silencing pathway in eukaryotic cells that involves an enzyme called dicer cleaving long pieces of double-stranded RNA into shorter fragments called siRNAs that can cleave complementary mRNA sequences with the help of the RISC complex and argonaute. RNA interference ...
Find More
Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in the US On November 15, 2022, Medtronic plc, a global leader in healthcare technology, announced the US launch of the Medtronic Extended infusion set, the first and only infusion set labeled for up to ...
Find More
Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...
Find More
Mitsubishi replacing RADICAVA’s Intravenous (IV) formulation with Oral. Opinion on Amylyx Pharma’s recent approval, RELYVRIO The amyotrophic lateral sclerosis treatment landscape is stringent and includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpoo...
Find More
Dementia is a leading neurological condition that affects the brain and worsens over time. It leads to progressive cognitive and functional degeneration and results in several neuropsychiatric symptoms. As per the estimate, about 55 million people globally live with dementia, and around 10 million new cases are obs...
Find More
DePuy Synthes Received FDA Approval for TELIGEN™ System On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...
Find More
The incidence and prevalence of traumatic spinal cord injury (SCI) worldwide have increased over time. As per the study by Weizhong Ding et al., globally, there were 0.9 million incident cases, 20.6 million prevalent cases, and 6.2 million YLDs of total SCI in 2019. Similarly, as per the data presented by WHO, ever...
Find More
Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....
Find More
Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....
Find More
Gene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Healt.....
Find MoreHear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.
